{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T06:12:24Z","timestamp":1788502344892,"version":"build-2803163510"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T00:00:00Z","timestamp":1788480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The aim of this study is to characterize reporting patterns and non-treatment drug safety signals for diabetes insipidus (DI) in the FDA Adverse Event Reporting System (FAERS), evaluate signal stability using crude, adjusted, and shrinkage-based disproportionality methods, and assess signal reproducibility in the Japanese Adverse Drug Event Report (JADER).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed FAERS (2004Q1\u20132025Q4) and JADER (2004\u20132025) reports. DI cases were defined by MedDRA Preferred Terms \u201cDiabetes insipidus\u201d and \u201cNephrogenic diabetes insipidus\u201d; central DI-related lower-level terms mapped to \u201cDiabetes insipidus\u201d and were not separately retrievable. Drugs used for DI diagnosis\/treatment or arginine vasopressin (AVP)-deficiency states were excluded during preprocessing. All eligible non-treatment primary suspect drug\u2013DI pairs were screened, and the main multi-method summary focused on the 50 most frequently reported drugs. Published cases were summarized as case-level evidence, not comparative risk meta-analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>FAERS contained 3,444 Preferred Term (PT)-defined DI reports; 3,325 entered the main non-treatment analysis. Raw annual counts increased, whereas normalized reporting proportions fluctuated. Complete screening identified 112 crude reporting odds ratio (ROR)-positive drug\u2013DI pairs. Among the frequency-ranked top 50, 47 met crude ROR criteria, 38 remained positive after adjustment, 32 met empirical Bayes geometric mean (EBGM) criteria, and 40 met information component (IC) criteria; in addition, 36 were positive in at least three methods. In JADER, 696 DI reports entered cross-database assessment; eight drugs met crude ROR criteria, eight met adjusted ROR criteria, three met EBGM criteria, and three met IC criteria. Lithium, hydrocortisone, and propofol were positive across all four JADER methods.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>After treatment-drug exclusion, DI reports clustered mainly among nervous system, antineoplastic\/immunomodulating, and systemic hormonal agents. Several non-treatment drugs showed persistent disproportionality, but JADER support was limited. These findings are hypothesis-generating signals, not causal evidence.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2026.1840741","type":"journal-article","created":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:28:37Z","timestamp":1788499717000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug spectrum and disproportionality signals for diabetes insipidus in FAERS: multi-method analysis, JADER cross-database assessment, and PubMed-based case-level evidence"],"prefix":"10.3389","volume":"17","author":[{"given":"Yiqi","family":"Li","sequence":"first","affiliation":[{"name":"Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhou","sequence":"additional","affiliation":[{"name":"Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinghe","family":"Tian","sequence":"additional","affiliation":[{"name":"Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deyi","family":"Wei","sequence":"additional","affiliation":[{"name":"Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Bi","sequence":"additional","affiliation":[{"name":"Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengyi","family":"Liu","sequence":"additional","affiliation":[{"name":"Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[{"name":"Bishan Hospital of Chongqing Medical University, Bishan Hospital of Chongqing","place":["Chongqing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S2213-8587(22)00219-4","article-title":"Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey","volume":"10","author":"Atila","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/s41574-024-00985-x","article-title":"Arginine vasopressin deficiency: diagnosis, management and the relevance of oxytocin deficiency","volume":"20","author":"Atila","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"602365","DOI":"10.3389\/fphar.2020.602365","article-title":"Machine learning for detection of safety signals from spontaneous reporting system data: example of nivolumab and docetaxel","volume":"11","author":"Bae","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"498","DOI":"10.3389\/fphar.2019.00498","article-title":"Suspected adverse drug reactions related to breast cancer chemotherapy: disproportionality analysis of the Brazilian spontaneous reporting system","volume":"10","author":"Barcelos","year":"2019","journal-title":"Front. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","article-title":"Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol","volume":"18","author":"Bate","year":"2009","journal-title":"Drug Saf."},{"key":"B6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1007\/s40290-019-00287-y","article-title":"Adverse drug reaction risk measures: a comparison of estimates from drug surveillance and randomised trials","volume":"33","author":"Beau-Lejdstrom","year":"2019","journal-title":"Pharm. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"107498","DOI":"10.1016\/j.intimp.2021.107498","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: an updated comprehensive disproportionality analysis of the FDA adverse event reporting system","volume":"95","author":"Chen","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"34","DOI":"10.5582\/ddt.2023.01092","article-title":"PD-1\/PD-L1 inhibitors associated hypophysitis: an analysis from the FAERS database and case reports","volume":"18","author":"Chen","year":"2024","journal-title":"Drug Discov. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41572-019-0103-2","article-title":"Diabetes insipidus","volume":"5","author":"Christ-Crain","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e001764","DOI":"10.1136\/bmjophth-2024-001764","article-title":"Prostaglandin analogues signal detection by data mining in the FDA Adverse Event Reporting System database","volume":"9","author":"Contreras-Salinas","year":"2024","journal-title":"BMJ Open Ophthalmol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s11096-023-01592-y","article-title":"Factors associated with underreporting of adverse drug reactions by patients: a systematic review","volume":"45","author":"Costa","year":"2023","journal-title":"Int. J. Clin. Pharm."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7925","DOI":"10.1007\/s00432-023-04659-5","article-title":"Immune checkpoint inhibitor-induced hypophysitis: clinical and biochemical features","volume":"149","author":"Esteves-Ferreira","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","article-title":"Case-non-case studies: principle, methods, bias and interpretation","volume":"74","author":"Faillie","year":"2019","journal-title":"Therapie"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1479764","DOI":"10.3389\/fendo.2024.1479764","article-title":"Central and nephrogenic diabetes insipidus: updates on diagnosis and management","volume":"15","author":"Flynn","year":"2025","journal-title":"Front. Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s40264-023-01302-7","article-title":"Factors associated with underreporting of adverse drug reactions by health care professionals: a systematic review update","volume":"46","author":"Garc\u00eda-Abeijon","year":"2023","journal-title":"Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/nrneph.2009.43","article-title":"Lithium nephrotoxicity revisited","volume":"5","author":"Gr\u00fcnfeld","year":"2009","journal-title":"Nat. Rev. Nephrol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1002\/pds.5265","article-title":"More extreme duplication in the U.S. FDA FAERS database and a suggested check point for disproportionality analysis","volume":"30","author":"Hauben","year":"2021","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf."},{"key":"B19","doi-asserted-by":"publisher","first-page":"e42866","DOI":"10.1371\/journal.pone.0042866","article-title":"A survey of the FDA's AERS database regarding muscle and tendon adverse events linked to the statin drug class","volume":"7","author":"Hoffman","year":"2012","journal-title":"PLoS One"},{"key":"B20","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1007\/s40264-014-0150-2","article-title":"The Weber effect and the United States Food and Drug Administration's Adverse Event Reporting System (FAERS): analysis of sixty-two drugs approved from 2006 to 2010","volume":"37","author":"Hoffman","year":"","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s40264-014-0225-0","article-title":"Stimulated reporting: the impact of US Food and Drug Administration-issued alerts on the Adverse Event Reporting System (FAERS)","volume":"37","author":"Hoffman","year":"","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"773135","DOI":"10.3389\/fphar.2021.773135","article-title":"Combining a pharmacological network model with a Bayesian signal detection algorithm to improve the detection of adverse drug events","volume":"12","author":"Ji","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.2169\/internalmedicine.2437-23","article-title":"Lithium-induced nephrogenic diabetes insipidus with efficacy of desmopressin in combination with thiazide diuretics and non-steroidal anti-inflammatory drugs: a case report with a review of the literature","volume":"63","author":"Jinnouchi","year":"2024","journal-title":"Intern. Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"420","DOI":"10.3390\/healthcare10030420","article-title":"A standardized dataset of a spontaneous adverse event reporting system","volume":"10","author":"Khaleel","year":"2022","journal-title":"Healthc. (Basel)"},{"key":"B25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/ki.2009.91","article-title":"Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus","volume":"76","author":"Kortenoeven","year":"2009","journal-title":"Kidney Int."},{"key":"B26","doi-asserted-by":"publisher","first-page":"154233","DOI":"10.1016\/j.jcrc.2022.154233","article-title":"Diabetes insipidus related to sedation in the intensive care unit: a review of the literature","volume":"75","author":"Kraus","year":"2023","journal-title":"J. Crit. Care"},{"key":"B27","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1177\/02537176221109962","article-title":"Diabetes insipidus induced by oral olanzapine at therapeutic dose","volume":"45","author":"Kumar","year":"2023","journal-title":"Indian J. Psychol. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41581-024-00897-z","article-title":"International expert consensus statement on the diagnosis and management of congenital nephrogenic diabetes insipidus (arginine vasopressin resistance)","volume":"21","author":"Levtchenko","year":"2025","journal-title":"Nat. Rev. Nephrol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"e0334317","DOI":"10.1371\/journal.pone.0334317","article-title":"Safety assessment of obinutuzumab: real-world adverse event analysis based on the FAERS and JADER databases from 2013 to 2025","volume":"20","author":"Li","year":"2025","journal-title":"PLoS One"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e250734","DOI":"10.1530\/EC-25-0734","article-title":"Real-world pharmacovigilance study of drug-induced diabetes insipidus from the FAERS database","volume":"15","author":"Lv","year":"2026","journal-title":"Endocr. Connect."},{"key":"B31","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/cpt.3701","article-title":"FDA Adverse Event Reporting System (FAERS) essentials: a guide to understanding, applying, and interpreting adverse event data reported to FAERS","volume":"118","author":"Potter","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"key":"B32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2701","DOI":"10.1210\/clinem\/dgac381","article-title":"Diagnosis and management of central diabetes insipidus in adults","volume":"107","author":"Tomkins","year":"2022","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B34","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1213\/ANE.0000000000005344","article-title":"Perioperative diabetes insipidus caused by anesthetic medications: a review of the literature","volume":"134","author":"Van Decar","year":"2022","journal-title":"Anesth. Analg."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0329385","DOI":"10.1371\/journal.pone.0329385","article-title":"Cancer-related adverse events associated with use of proton pump inhibitors and histamine-2 receptor antagonists: a real-world analysis using the FDA adverse event reporting system","volume":"20","author":"Wang","year":"2025","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/s41698-025-01123-0","article-title":"A real-world cohort study of immune-related adverse events in patients receiving immune checkpoint inhibitors","volume":"9","author":"Wang","year":"2025","journal-title":"Npj Precis. Oncol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.3760\/cma.j.issn.0578-1426.2018.03.010","article-title":"Clinical characteristics of central diabetes insipidus: a retrospective analysis of 230 cases","volume":"57","author":"Zhang","year":"2018","journal-title":"Zhonghua Nei Ke Za Zhi"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1840741\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T05:28:39Z","timestamp":1788499719000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1840741\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,4]]},"references-count":37,"alternative-id":["10.3389\/fphar.2026.1840741"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1840741","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,4]]},"article-number":"1840741"}}